Access Hope CRO in the News

Regulatory Affairs Professional Society (RAPS) recently interviewed Access Hope CRO CEO, Richard Garr, in the "Right to Try One Year Later: Limited Patient Involvement but More FDA Clarity Coming" article posted on May 30, 2019.

Here's an excerpt from the article:

Richard Garr, CEO of Access Hope CRO, a niche contract research organization dedicated exclusively to Right to Try treatment programs, told Focus via email that he’s spent the past six months building a network of national and regional clinics, hospital chains and physician practices that will treat patients under Right to Try.

“They run the gamut from various oncology indications to ALS and Alzheimer's and even some psychiatric diseases that can lead to suicide and thus are potentially fatal,” he said. 

And by the end of June, Garr expects to launch a website and patient-facing portal. Patients will begin to be treated for several indications under the law later this summer, he said.

“The first to come on-line will be an ALS program and I expect to treat between 200 and 300 patients for this particular program over the next 12 months in the Southeast. The sponsor may expand the program nationally,” he added. “Companies are doing this in exchange for data which provide pre-approval insights to guide their traditional clinical trial programs. And as we are doing this at scale, I expect it will impact large numbers of patients.”

But he did not offer any specifics on companies offering treatments, explaining all programs are "confidential, and only the sponsors can make their information public if they so chose."  

To read the full article: LINK